Societal views on nice, cancer drugs fund and value-based pricing criteria for prioritising medicines: A cross-sectional survey of 4118 adults in great britain

Health Economics (United Kingdom)

Volumn 22, Issue 8, 2013, Pages 948-964

  Linley, Warren G ^a   Hughes, Dyfrig A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

cancer drugs fund; equity; health care rationing; NICE; orphan drugs; public preferences; value based pricing

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER THERAPY; CHILD CARE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; MALE; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; RARE DISEASE; RESOURCE ALLOCATION; SOCIETY; UNITED KINGDOM; WEB BROWSER;

CANCER DRUGS FUND; EQUITY; HEALTH CARE RATIONING; NICE; ORPHAN DRUGS; PUBLIC PREFERENCES; VALUE-BASED PRICING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUG COSTS; FEMALE; GREAT BRITAIN; HEALTH PRIORITIES; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RESOURCE ALLOCATION; VALUE-BASED PURCHASING; YOUNG ADULT;

EID: 84880132926     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.2872     Document Type: Article

References (41)

1. All Wales Medicines Strategy Group. 2011. AWMSG policy relating to ultra-orphan medicines. Available: http://www.wales.nhs.uk/sites3/Documents/371/ AWMSG%20policy%20relating%20to%20Ultra-orphan%20Medicines%20Sep%2011.pdf [09 May 2012].
2. Buxton MJ, Chambers JD,. 2011. What values do the public want their health care systems to use in evaluating technologies? (Editorial). European Journal of Health Economics 12: 285-288.
3. Coleman MP, Forman D, Bryant H, et al,. 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007 (The International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377: 127-138.
4. Department of Health. 2009. NHS Chief Executive's Annual Report for 2008-09, May 2009. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/documents/digitalasset/dh-099700.pdf [15 July 2012].
5. Department of Health. 2010a. The NHS Constitution for England. Available: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-113613 [09 May 2012].
6. Department of Health. 2010b. Impact assessment of a proposal for a Cancer Drugs Fund. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@en/documents/digitalasset/dh-120930.pdf [09 May 2012].
7. Department of Health. 2010c. Value-based pricing impact assessment. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-122823.pdf [09 May 2012].
8. Department of Health. 2010d. A new value-based approach to the pricing of branded medicines: a consultation. Available: http://www.dh.gov.uk/en/ Consultations/Closedconsultations/DH-122760 [09 May 2012].
9. Department of Health. 2010e. The Cancer Drugs Fund: a consultation. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-120931.pdf [09 May 2012].
10. Department of Health. 2011. A new value-based approach to the pricing of branded medicines-Government response to consultation. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-128404.pdf [09 May 2012].
11. Desser A, Gyrd-Hansen D, Olsen AJ, Grepperud S, Kristiansen IS,. 2010. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. British Medical Journal 341: c4715.
12. Dolan P, Tsuchiya A,. 2007. The elicitation of distributional judgements in the context of economic evaluation. In: The Elgar companion to Health Economics, Jones AM, (ed). Edward Elgar Publishing Ltd, UK: Cheltenham, 382-391.
13. Dolan P, Shaw R, Tsuchiya A, Williams A,. 2005. QALY maximisation and people's preferences: a review of the literature. Health Economics 14: 197-208.
14. Fontain N, Hemila K,. 2000. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Official Journal of the European Communities. Available: http://ec.europa.eu/ health/files/eudralex/vol-1/reg-2000-141/reg-2000-141-en.pdf [09 May 2012].
15. Foot C, Harrison T,. 2011. How to improve cancer survival: explaining England's relatively poor rates. The King's Fund. Available: http://www.kingsfund.org.uk/publications/cancer-survival.html [09 May 2012].
16. th Biennial Society for Medical Decision Making European Meeting; Austria [abstract No.1].
17. Hughes D,. 2011. Value-based pricing: incentive for innovation or zero net benefit? PharmacoEconomics 29: 731-735.
18. Hughes D, Duerden M,. 2011. Ring-fencing a budget for cancer drugs: is it fair? Against. Journal of the Royal College of Physicians of Edinburgh 41: 226-228.
19. Institute for Fiscal Studies/Nuffield Trust. 2012. NHS and social care funding: the outlook to 2021/22. Available: http://www.nuffieldtrust.org.uk/ sites/files/nuffield/publication/120704-nhs-social-care-funding-outlook-2021-22- 0.pdf [15 July 2012].
20. Johnson TP, Wislar JS,. 2012. Response rates and nonresponse errors in surveys. JAMA: The Journal of the American Medical Association 307: 1805-1806.
21. Kind P, Hardman G, Macran S,. 1999. UK population norms for EQ-5D. Discussion Paper 172, University of York Centre for Health Economics. Available: http://www.york.ac.uk/media/che/documents/papers/discussionpapers/ CHE%20Discussion%20Paper%20172.pdf [09 May 2012].
22. Linley WG, Hughes DA,. 2012. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. Pharmacoeconomics 2012 Jun 7. doi: 10.2165/11591530-000000000-00000. [Epub ahead of print].
23. Mason A, Drummond M, Ramsey S, et al,. 2010. Comparison of anticancer drug coverage decisions in the United States and the United Kingdom: does the evidence support the rhetoric? Journal of Clinical Oncology 28: 3234-3238.
24. McCabe C, Claxton K, Tsuchiya A,. 2005. Orphan drugs and the NHS: should we value rarity. British Medical Journal 331: 1016-1019.
25. McColl E, Jacoby A, Thomas L, et al,. 2001. Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technology Assessment 5 (31): 1-256.
26. National Institute for Health and Clinical Excellence. 2008a. Guide to the methods of technology appraisal. Available: http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdatedJune2008.pdf [09 May 2012].
27. nd Ed. Available: http://www.nice.org.uk/media/C18/30/ SVJ2PUBLICATION2008.pdf [09 May 2012].
28. National Institute for Health and Clinical Excellence. 2008c. Report on NICE Citizens Council meeting: departing from the threshold. Available: http://www.nice.org.uk/media/231/CB/NICECitizensCouncilDepartingThresholdFinal. pdf [09 May 2012].
29. National Institute for Health and Clinical Excellence. 2009. Supplementary advice to the appraisal committees: appraising life-extending, end of life medicines. Available: http://www.nice.org.uk/media/E4A/79/ SupplementaryAdviceTACEoL.pdf [09 May 2012].
30. National Readership Survey. 2010. NRS 2010 lifestyle data. Available: http://www.nrs.co.uk/lifestyle.html [09 May 2012].
31. NHS Specialised Services. 2011. National specialised commissioning priorities 2011/12. Available: http://www.specialisedservices.nhs.uk/library/21/ National-Specialised-Commissioning-Priorities-201112.pdf [09 May 2012].
32. Office for National Statistics. 2009. General lifestyle survey 2009. Available: http://www.ons.gov.uk/ons/rel/ghs/general-lifestyle-survey/2009- report/index.html [09 May 2012].
33. Office for National Statistics. 2010. Nomis official labour force statistics: headline indicators 2011/12. Available: http://www.nomisweb.co.uk/ tml/templates/data/LFS%20headline%20indicators.xls [09 May 2012]
34. Office for National Statistics. 2011. Mid-2010 population estimates for adults aged 16 years and over. Available: http://www.ons.gov.uk/ons/rel/pop- estimate/population-estimates-for-uk - england-and-wales - scotland-and- northern-ireland/mid-2010-population-estimates/rft - -mid-2010-population- estimates.zip [09 May 2012].
35. Rawlins M, Barnett D, Stevens A,. 2010. Pharmacoeconomics: NICE's approach to decision-making. British Journal of Clinical Pharmacology 70: 346-349.
36. Richards M,. 2008. Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards CBE. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-089952.pdf [09 May 2012].
37. Scottish Medicines Consortium. 2010. SMC modifiers used in appraising new medicines. Available: http://www.scottishmedicines.org.uk/About-SMC/Policy- Statements/SMC-Modifiers-used-in-Appraising-New-Medicines [09 May 2012].
38. Shah KK,. 2009. Severity of illness and priority setting in healthcare: a review of the literature. Health Policy 93: 77-84.
39. Stiggelbout AM, de Vogel-Voogt E,. 2008. Health state utilities: a framework for studying the gap between the imagined and the real. Value in Health 11: 76-87.
40. Walker A, Booth C, Brown A, et al,. 2009 How much good do new medicines do? Basic & Clinical Pharmacology & Toxicology 105 (Suppl 1): O29.
41. Webb DJ,. 2011. Value-based pricing: NICE work? Lancet 377: 1552-1553.